RCC_Evo SIGNED
Modelling the Predictability and Repeatability of Tumour Evolution in Clear Cell Renal Cell Cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RCC_Evo project word cloud
Explore the words cloud of the RCC_Evo project. It provides you a very rough idea of what is the project "RCC_Evo" about.
Project "RCC_Evo" data sheet
The following table provides information about the project.
| Coordinator |
THE FRANCIS CRICK INSTITUTE LIMITED
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 224˙933 € |
| EC max contribution | 224˙933 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2019 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-04-01 to 2022-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE FRANCIS CRICK INSTITUTE LIMITED | UK (LONDON) | coordinator | 224˙933.00 |
Map
Project objective
Kidney cancer is among the 10 most frequently diagnosed cancers and its incidence is rising. Clear cell Renal Cell Cancer (ccRCC) is the most common subtype and is characterized by early 3p loss. The deleted region on chromosome 3p harbours a number of tumour suppressor genes namely VHL, PBRM1, SETD2 and BAP1, which are frequently mutated subsequent to 3p loss. TRACERx Renal is a multi-center, longitudinal cohort study, which studies tumour evolution and intratumoural heterogeneity through multi-region profiling of primary tumours. Interim findings have defined 7 evolutionary subtypes. I will model the predictability and repeatability of these evolutionary trajectories in patient-derived tumour organoids (PDO), in patient-derived xenografts (PDX), and in gene-edited human proximal tubule cells (HPTC). Preliminary evidence suggests that ccRCC genotypes are associated with specific TME conditions. I will develop PDO models in which I will co-culture tumour cells with tumour infiltrating leucocytes and cancer associated fibroblasts. I will refine the mutational ordering and clonal resolution in selected cases of the TRACERx Renal Study by micro-biopsy profiling. Predictability of evolutionary trajectories will then be addressed through repeated passaging of tumour PDOs followed by targeted panel sequencing. The function of metastatic driver events will be characterised in PDX. The repeatability of the evolutionary trajectories will be studied through experimental manipulation of the genotype sequence in HPTCs. Co-culture PDOs will be used to define response to immune checkpoint inhibition. The results will allow a personalized prediction of the clinical course of ccRCC and the response to immune checkpoint inhibition. I will identify mechanisms of tumour progression and the involvement of the TME. This will result in the identification of previously unknown targetable weaknesses in ccRCC.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RCC_EVO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RCC_EVO" are provided by the European Opendata Portal: CORDIS opendata.